PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 1, 20261 citations

Discovery of Casdatifan, Part I: Design and Characterization of Tetrahydroquinoline Inhibitors of Hypoxia-Inducible Factor-2α.

View Full Paper
GMGuillaume MataAMArtur K. MailyanSDSamuel L. Drew

Key Points

  • The aim is to design and characterize tetrahydroquinoline inhibitors of hypoxia-inducible factor-2α.
  • Focused on difluorination to enhance binding efficiency
  • Analyzed hyperconjugative effects and physicochemical properties
  • Evaluated biochemical and cellular activities
  • Demonstrated improved binding efficiency and inhibition of hypoxia-regulated gene expression
  • Identified casdatifan as a clinical-stage HIF-2α inhibitor
  • Supported potential clinical applications based on novel chemotype

Abstract

difluorination was critical for productive engagement of the lipophilic pocket, with hyperconjugative effects contributing to improved binding efficiency and facial polarization enhancing physicochemical properties. These features translated into improved biochemical and cellular activity, including inhibition of hypoxia-regulated gene expression. Insights from this campaign ultimately informed the discovery of casdatifan, a clinical-stage HIF-2α inhibitor, underscoring the translational potential of this novel chemotype.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mata et al. (2026) studied this question.

synapsesocial.com/papers/69f443e8967e944ac5566f4ahttps://doi.org/10.1021/acs.jmedchem.5c03647
Ask AI
Helpful
Bookmark
Share
View Full Paper